Tirzepatide peptide vial
⚖️ Weight Management

Tirzepatide

Tirzepatide (GIP/GLP-1 Dual Receptor Agonist)

Also called Mounjaro, Zepbound, GIP/GLP-1 dual agonist, tirzepatida

The two-hormone drug behind Mounjaro and Zepbound

Tirzepatide is a once-weekly injection sold as Mounjaro for type 2 diabetes and Zepbound for weight loss. It copies two gut hormones instead of one, and produced more weight loss than semaglutide when the two were compared directly. It is an approved medicine with large trials behind it, which makes it unusual on this site.

A weekly injection for weight loss and type 2 diabetes, sold as Zepbound and Mounjaro. It copies two of the gut hormones that tell your brain you have eaten enough, where most drugs in this class copy one. When the two were compared directly in SURMOUNT-5, tirzepatide produced about 20% loss of body weight against 13.7% for semaglutide over 72 weeks.

Half-life
About 5 days
Route studied
Subcutaneous injection (label)
Status
Prescription (Mounjaro, Zepbound)
Strong Evidence

Tested in several human trials

2,315 papers · 137 clinical trials

What Tirzepatide has been studied for

The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.

Weight loss
Approved as Zepbound for chronic weight management. In SURMOUNT-1, the 15 mg group lost about 21% of body weight over 72 weeks.
Type 2 diabetes
Its original approved use, sold as Mounjaro, where it lowers blood sugar and weight together.
Obstructive sleep apnoea
An approved use for Zepbound, after two trials showed large falls in breathing interruptions during sleep.
Progression to diabetes
In the three-year SURMOUNT-1 follow-up of people with obesity and prediabetes, 1.3% on tirzepatide developed type 2 diabetes against 13.3% on placebo.

Mechanism of Action

How Tirzepatide works

Your gut talks to your brain about food. When you eat, it releases hormones that travel up and say, in effect, that's enough. Those signals fade fast, which is part of why a meal stops feeling like enough about twenty minutes after it should.

Semaglutide copies one of those hormones. Tirzepatide copies two.

What the second one adds

The first signal, GLP-1, is the appetite one. It reaches the parts of the brain that set hunger, slows how fast your stomach empties so food sits with you longer, and tells the pancreas to release insulin only when blood sugar is actually up. That last detail is why it does not tip you into a hypo the way older diabetes drugs could: it responds to sugar rather than ignoring it.

The second signal, GIP, is the one tirzepatide adds and semaglutide does not have. It seems to make the body handle fat and insulin better, and it appears to take some of the edge off the nausea rather than adding to it, which is not what you would expect from combining two appetite hormones.

That is the whole argument for the molecule, and unusually for this field it was tested head to head rather than asserted. Against semaglutide over 72 weeks, tirzepatide produced roughly 20% weight loss to semaglutide's 13.7%.

What it does not do

It does not change what your body does with food permanently. In the trial where people were switched to placebo, the weight came back. It is labelled as a long-term treatment, not a course you complete.

Tirzepatide side effects: what studies reported

Almost everything reported in the trials is digestive, and most of it happened during the dose escalation period rather than afterwards.

Most commonly reported

  • Nausea
  • Constipation
  • Diarrhoea
  • Burping and reflux
  • Feeling full very quickly
  • Tiredness

Worth keeping an eye on

  • Losing muscle along with fat
  • Hair shedding a few months in, which usually tracks the speed of weight loss rather than the drug itself
  • Gallstones, more likely when weight comes off fast
  • Low blood sugar when combined with insulin or a sulfonylurea, a labelled interaction

Reasons to call someone

  • Severe stomach pain that goes through to your back and does not ease, which is how pancreatitis presents
  • Vomiting so persistent you cannot keep fluids down

Dose-related findings. In the SURMOUNT trials, gastrointestinal effects were more frequent at higher doses and during dose escalation.

Source: SURMOUNT and SURPASS trial programmes, plus widespread prescribing experience. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about Tirzepatide belong with a licensed clinician who knows your history.

Your Genetics & Tirzepatide

The genes involved in how Tirzepatide works

Tirzepatide works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.

Chromosome 19GIP receptor signaling (the dual-agonist differentiator)

GIPR · ••

The Glu354Gln (E354Q) variant has been associated with differences in GIP receptor signalling and with lower body mass index in population studies. GIP is the half of tirzepatide that semaglutide lacks, so this gene is relevant here and not for semaglutide. No study has shown that it predicts response to tirzepatide or should guide a choice between drugs.

Chromosome 6GLP-1 receptor sensitivity

GLP1R · ••

The Gly168Ser variant sits in the GLP-1 receptor, the half tirzepatide shares with semaglutide. Some cohort studies of GLP-1 drugs have associated it with differences in weight loss, with inconsistent results. It has not been studied as a predictor for tirzepatide.

Chromosome 10Beta-cell function and insulin secretion

TCF7L2 · ••

The common variant most strongly linked to type 2 diabetes risk; T-allele carriers tend to release less insulin after meals. It is studied as a possible modifier of blood-sugar response to diabetes drugs, and is not established as one for tirzepatide.

ARRB1Receptor desensitization

Beta-arrestin 1 is involved in pulling incretin receptors back inside the cell after activation. Any effect of this variant on tirzepatide response is a hypothesis; it has not been tested.

The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.

Which of these variants do you carry?

Your report reads the DNA file you already have against this research.

Read my DNA, $99

Access

Access and legal status

Tirzepatide: Prescription (Mounjaro, Zepbound). Decisions about any prescription medicine belong to a prescriber. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.

Your DNA and Tirzepatide: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →

Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.

Worth knowing about Tirzepatide

Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.

Nausea and other gut effects are the usual reason people stop
Across the trials the most common problems were gastrointestinal: nausea, diarrhoea, constipation and vomiting. Most were mild to moderate and clustered in the first weeks of dose escalation.
Compounded versions are not the trialled drug
Every result on this page comes from the manufacturer's product. Compounded tirzepatide is a different preparation that has not been through those trials, and FDA has warned about dosing errors with compounded GLP-1 products.
Weight came back after stopping
In the trial that withdrew treatment (SURMOUNT-4), weight was regained. That is a finding about the drug rather than about willpower: stopping returns the appetite signalling to where it started.

The evidence behind Tirzepatide

Along with semaglutide, this is as good as evidence gets on this site. Tirzepatide has been through multiple phase 3 trials in thousands of people, published in the New England Journal of Medicine, JAMA and the Lancet, and it is an approved medicine rather than a research chemical. Where other pages flag preclinical-only data, here the question is which human trial population a finding came from.

The literature, counted

Counted in PubMed on 3 August 2026 for tirzepatide. Every figure links to the search that produced it, so you can re-run it. “Tagged human” is not the same as a human trial: that tag also covers work on human cells and reviews discussing people, which is why the trial count is given separately.

Studied in people

3 of 8The only kind that directly answers whether it works in humans.
  1. New England Journal of Medicine · 2022

    Human

    Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff AM, Aronne LJ, Ahmad NN, et al.

    The trial the weight-loss claims rest on, known as SURMOUNT-1. At the 15 mg dose the average loss was about 21% of body weight against 3.1% on placebo. Put another way, 57% of people on 15 mg lost at least a fifth of their body weight, compared with 3% on placebo.

    Phase 3 · n=2,539 · 72 weeks

    Read the paper
    Tirzepatide Once Weekly for the Treatment of Obesity: source for Tirzepatide (opens in a new tab)
  2. New England Journal of Medicine · 2025

    Human

    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    Aronne LJ, Horn DB, le Roux CW, et al.

    The head-to-head against semaglutide. Tirzepatide produced roughly 20% weight loss against 13.7% for semaglutide, and 18.4 cm off the waist against 13.0 cm.

    Phase 3b · 72 weeks

    Read the paper
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: source for Tirzepatide (opens in a new tab)
  3. New England Journal of Medicine · 2025

    Human

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al.

    Followed SURMOUNT-1 participants for three years. Among those with obesity and prediabetes, 1.3% on tirzepatide went on to develop type 2 diabetes compared with 13.3% on placebo. A large difference in a hard clinical outcome, not only in weight.

    Phase 3 · n=2,539 · 3 years

    Read the paper
    Tirzepatide for Obesity Treatment and Diabetes Prevention: source for Tirzepatide (opens in a new tab)
Every source behind this page8
  1. Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityMalhotra A, Grunstein RR, Fietze I, et al. · New England Journal of Medicine · 2024 · Phase 3Human
  2. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialRosenstock J, Wysham C, Frías JP, et al. · Lancet · 2021 · Phase 3Human
  3. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialAronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024 · Phase 3Human
  4. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialGarvey WT, Frias JP, Jastreboff AM, et al. · Lancet · 2023 · Phase 3Human
  5. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trialWadden TA, Chao AM, Machineni S, et al. · Nature Medicine · 2023 · Phase 3Human

Everything we cite for Tirzepatide, including preclinical work and early research. Each link goes to the source itself, so you can judge it rather than take our word for it.

Last updated · literature counts verified against PubMed on

Frequently Asked Questions

How does tirzepatide compare with semaglutide?

In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks (about 20% against 13.7%). The likely reason is the added GIP signal. Semaglutide is the one with a completed cardiovascular outcomes trial in people without diabetes (SELECT). Individual results vary, nobody can predict them, and choosing between prescription drugs belongs to a prescriber.

Do genes affect tirzepatide response?

No variant is established as a predictor of response to tirzepatide. GIPR is the gene most specific to it, because GIP is the signal semaglutide lacks, and its variants have been associated with body mass index in population studies. GLP1R and TCF7L2 relate to the GLP-1 and blood-sugar side. A DNA report can show which versions you carry and what that research does and does not show.

Does tirzepatide interact with CYP enzyme genetics?

No. Like semaglutide, tirzepatide is a peptide cleared by general protein-cutting enzymes, not by cytochrome P450 enzymes, so CYP gene variants do not affect how it is cleared.

Learn more about Tirzepatide

11 guides mention Tirzepatide→

Your DNA and Tirzepatide

What the research says about your variants.

The report

Which Tirzepatide variants do you carry?

Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.

Read my DNA, $99
Upload your DNA